Recommendations for the Clinical Management and Prevention of Pediatric Cannabis Edible Ingestions

Abstract

Cannabis edible products pose significant health risks to children due to a wide variety of reasons. Currently, there is inconsistent governmental regulation and oversight for the manufacturing, packaging, and labeling of these products. Additionally, consumer education and harm reduction strategies are lacking, leading to an increase in the incidence of unintentional cannabis edible ingestions by the pediatric population. The variation of the components and potencies of cannabis products causes a wide range of dose-dependent adverse events within this patient population. This poses a significant challenge for clinicians treating pediatric patients who present with signs and symptoms consistent with cannabis intoxication. This article provides medical and pharmacological context on the current state of cannabis edibles in the United States, with further recommendations for the initial screening, management, and prevention of cannabis ingestions by pediatric patients.

Introduction

As of January 1, 2025, 24 states and Washington, DC, have legalized recreational cannabis use.¹ Attitudes toward cannabis have become more permissive, driving support for legalization and retail use.² Natural and synthetic cannabinoids come in various oral forms, such as oils, concentrates, distillates, and edibles, with varying active compounds.³ Delta-9-tetrahydrocannabinol (Δ9-THC), the main psychoactive component in marijuana, is extracted and used in edible products such as butters, oils, or gelatins.^4,5 While smoking or vaping cannabis remains common, edibles are gaining popularity as a perceived safer alternative to avoid respiratory risks.^6,7 Studies show increased discussions about edibles on platforms, like Reddit, and higher use among adolescents in the United States.^6–8 A 2018 survey found that 55.6% of 1500 cannabis users consumed edibles.⁹ In Colorado’s first year of legalized sales in 2014, 86% of infused products sold were edibles, totaling 4.81 million units.^7,10 Increased retail access raises concerns that edibles may resemble commercialized food products, posing risks to children.²

Pediatric hospital admissions for accidental cannabis exposures have risen sharply in recent years. Between 2017 and 2021, cannabis exposures in children aged 5 and younger increased by 1375%, with 90.1% occurring in the child’s home.¹¹ During this period, 7043 cases of cannabis exposure were reported in children under 6, often requiring critical care.^11,12 These incidents have increased in states with legalized and commercialized cannabis.¹²

State-specific cannabis laws result in inconsistent manufacturing and possession regulations. Disparities in production practices and product batches, along with limited quality control, complicate clinicians’ ability to assess risks and outcomes for pediatric patients.¹³ The rise in pediatric cannabis ingestions is linked to the increasing prevalence of cannabis edible products. This article reviews the pharmacology and pharmacokinetics of cannabis edibles, offers guidance for managing pediatric intoxications, and provides tools for clinicians, such as patient screening questions, along with harm reduction/prevention strategies for consumers.

Case Presentation

A 15-month-old, 10-kg male child, born full-term and without a significant past medical history, presented to the emergency room with altered mental status and cyanosis. The child’s parents reported that he had eaten a cannabis brownie before these symptoms began. They admitted to recreational cannabis use and keeping cannabis edible brownies, cereal, cookies, and gummy candy, with packaging resembling commercial snacks, in their bedroom. They were unaware of the brownie’s tetrahydrocannabinol (THC) content and could not provide the package label. The child’s parents reported that approximately 30 minutes post ingestion, the child began to experience increased drowsiness and labored respirations. Emergency medical services were called, and the child was rushed to the emergency department after being observed struggling to breathe and turning “blue.” Vitals obtained by emergency medical services revealed a depressed respiratory rate of 12 and tachycardia with a heart rate of 145 beats per minute. En route to the hospital, the child was administered a dose of naloxone due to concerns of impending respiratory failure secondary to a suspected coingestion of opioids.

On examination, the child was lethargic and difficult to arouse. Conjunctivae were injected bilaterally. Vital signs in the emergency department were significant for tachycardia with heart rates ranging from 145 to 150 beats per minute. In contrast, body temperature, respiratory rate, blood pressure, and oxygen saturations remained within normal parameters. The remainder of his physical examination was unremarkable.

Work-up for the child included an electrocardiogram, which revealed sinus tachycardia. A point-of-care glucose test and a venous blood gas were obtained and were within normal limits. A comprehensive urine and blood drug screen was obtained, which yielded positive results for THC cannabinoids, suggesting a probable ingestion of cannabis edibles. Toxicology was consulted for further recommendations, and the child was admitted to a pediatric intensive care unit for an observation period, with close monitoring of heart rate, respiratory rate, and oxygen saturation. Social work and the Child Protection Team were consulted, and a report was submitted to the Department of Human Services due to concern for an overdose with potential for a near fatality. The child was medically cleared after the observation period was completed. The child, without further incidents, was eventually discharged to kinship care with a close family relative as parental custodial rights were restricted after the accidental ingestion incident and investigation.

Cannabinoids: Receptors, Effects, and Pharmacokinetic Properties

The human body produces 2 endogenous cannabinoids, anandamide and 2-arachidonoylglycerol, which bind to the CB1 and CB2 receptors, both G-protein coupled. CB1 is primarily in the central nervous system and peripheral nerves, influencing pain signaling, and CB2 is found in immune cells and tissues.^14,15 Both of these receptors are part of the body’s endocannabinoid system, which is responsible for homeostasis and many other bodily functions. Cognitive functions such as memory and learning, as well as the regulation of mood, anxiety, and perception of pain, are all modulated by this system.¹⁵ Differences exist in CB1 receptor amount and location during fetal development, childhood, and into adulthood.^16,17

There is a wide range of natural and synthetic compounds that interact with CB1 and CB2 receptors, with the 2 most notable being Δ9-THC and cannabidiol (CBD).¹⁸ Delta-9-THC is primarily responsible for the psychoactive properties of cannabis, and CBD displays significant efficacy in reducing pain perception and inflammation. Delta-9-THC is a partial agonist of both the CB1 and CB2 receptors, and CBD shows little affinity for the orthosteric site of either receptor.¹⁵ The use of Δ9-THC can lead to impairments in simple cognitive functions, including memory, learning, and motor coordination, as well as more complex tasks, such as problem solving and decision making. Several factors, including the age of the individual using cannabis and the amount used, can affect the extent to which these functions are negatively affected.¹⁹ In the pediatric population, these effects may have profound, varied, and wide-reaching consequences, especially on young and developing brains. Some patient cases report seizures in children after the accidental ingestion of cannabis edibles.^11,20

The pharmacokinetics of cannabis edibles vary between individuals, as Δ9-THC and CBD interact with the body differently, making clinical interpretation challenging. Treating these components as distinct entities helps clarify their effects. However, most data come from adult studies, with limited pediatric research, complicating the management of pediatric cannabis ingestion or intoxication cases. In general, Δ9-THC and CBD have delayed onsets with protracted durations of action. Both exhibit similar distribution profiles and metabolic pathways with various routes of elimination and excretion. Specific pharmacokinetic properties of Δ9-THC and CBD, derived from adult subjects, including their onset, bioavailability, duration of action, distribution, metabolism, excretion, and half-lives, can be found in Table 1.^14,18,21,22

Table 1.

Pharmacokinetic Properties of Δ9-THC and CBD^*

Molecule	Δ9-THC	CBD	References
Onset (oral)	30–120 min	Several hours	Δ9-THC14,21 CBD14
Bioavailability (oral)	4%–20%, increased up to 25% with high fat meal.	6%–33%	Δ9-THC14,21 CBD14,18
Duration of action (oral)	5–8 hours	12–24 hours	14
Distribution profile	Not well understood. Studies propose anywhere from 2–6 compartments. Initially concentrates in blood with 90% found in plasma. Distributes to and accumulates in highly perfused organs and fatty tissues as time passes.	Similar to Δ9-THC, distributes into fatty tissues and well-perfused organs.	14,18
Metabolism	Rate of metabolism and clearance is dependent on the individual’s sex, frequency of cannabis use, and hepatic function. Metabolized by CYP450 enzymes: CYP2C9, 2C19, 2D6, and 3A4. Glucuronidation via phase 2 metabolic pathways.	Metabolized by CYP450 enzymes: CYP1A1, 1A2, 2B, 2C9, 3A4, and 2D6. Glucuronidation via phase 2 metabolic pathways and through hydroxylation.	Δ9-THC14,18 CBD14,22
Excretion	Eliminated at a protracted rate due to slow diffusion out of areas where it has accumulated. 20%–35% of metabolites are excreted in urine. 65%–80% of metabolites are excreted in feces. <5% is excreted as unaltered Δ9-THC in feces.	Excreted in the feces in larger amounts than Δ9-THC. Some excreted in urine.	Δ9-THC14,18 CBD14,22
Half-life	20–30 hours Metabolite half-lives vary.	18–32 hours Metabolite half-lives vary.	14

Δ9-THC, delta-9-tetrahydrocannabinol; CBD, cannabidiol; CYP450, cytochrome P450

^*Data provided have been derived from human subjects. There are insufficient data available to provide a specific time frame for the onset of oral CBD products.

Patient Presentations

Edible cannabis products have been linked with numerous hospital visits for intoxication across all ages, with children at particular risk. Children often cannot distinguish cannabis edibles from regular snacks, increasing the likelihood of unknowingly consuming high, potentially toxic doses. In addition, the delayed onset of action for both Δ9-THC and CBD in oral cannabis products can be extremely problematic for the pediatric population, as caregivers may not realize that their child has ingested cannabis edibles until they display signs and symptoms of intoxication.²³ Pediatric patients are at an increased risk for poor outcomes due to the dangers noted, as well as the fact that this population is known to have a lower threshold for toxic cannabis doses when compared with adults.²⁴ All of these factors create a challenge for clinicians who are tasked with the management of pediatric patients who ingest cannabis edibles.²⁵

In adolescents, acute cannabis intoxication presents with symptoms, such as tachycardia, tachypnea, conjunctival injection, dry mouth, increased appetite, ataxia, and slurred speech.² There may also be neuropsychiatric effects, such as euphoria, relaxation, decreased attention, anxiety, paranoia, or depersonalization.²⁶

The effects of cannabis intoxication in the pediatric population can vary greatly and are partly related to potency and dosing relative to the patient’s body weight. In pediatric patients (<12 years old), the effects of acute cannabis intoxication typically present as altered mental status.²⁷ Tremors, ataxia, lethargy, somnolence, and seizures have also been reported in this population. History often describes significant difficulties with being able to arouse a child when found by a caregiver, which plays a role in the initial approach, triaging, work-up, and management of cannabis intoxication in the pediatric setting.² Given that common signs and symptoms of severe cannabis intoxication (e.g., lethargy and encephalopathy) can also resemble postictal states or encephalitis, broad work-ups with a multitude of blood tests and invasive diagnostic procedures may be necessary. This often delays the prompt, accurate diagnosis of cannabis intoxication.²⁷

Medical Management

Acute cannabis intoxication in children and adults is diagnosed through clinical presentation and diagnostic testing, with a thorough event and personal medical history being essential. Open-ended, nonjudgmental questions should address ingestion timing, symptom onset and progression, dosage or form of the consumed substance, location of exposure, other potential toxins, recent medications, and medical history. Additional recommendations and specific screening questions are outlined in the “Recommendations and Future Considerations” section. Management primarily relies on supportive care tailored to the patient’s presentation and clinical course. Given that altered mental status in children has a broad differential diagnosis, prompt stabilization and a detailed interval history are crucial for effective medical care.

Patients with lethargy, respiratory depression, cardiac abnormalities, or those who are at risk of coma should have their airway secured, receive supplemental oxygen, and have appropriate vascular access. Vascular access is essential when intravenous fluids and/or medications are needed. If a patient presents with altered mental status and respiratory depression, naloxone can be beneficial as both an interventional and diagnostic tool, especially if opioid ingestion or coingestion is suspected. Before gaining intravenous access, 4 mg of naloxone can be given intranasally to infants, children, and adolescents and repeated every 2 to 3 minutes as needed for opioid-induced respiratory depression. Intramuscular administration of naloxone may also be a viable option, depending on the patient’s relative muscle mass, for adequate absorption. Naloxone, however, can only act by reversing any opioids in the patient’s system and will not reverse the effects of cannabis intoxication.²⁸

The initial assessment in patients of any age who present with an altered mental status, especially lethargy, includes electrolytes and an arterial/venous blood gas. A point-of-care rapid blood glucose test is a quick and inexpensive test to rule out hypoglycemia, which can often present with signs and symptoms of lethargy and/or seizures. Given the frequency of acute cannabis toxicity presenting as an unknown ingestion and/or accidental poisoning, a standard urine drug screen is an effective initial first-line test.¹² Other accompanying tests may include an electrocardiogram (to rule out cardiac causes such as arrhythmia) and a serum toxicology panel, which includes acetaminophen, salicylates, and ethanol levels.²⁷

Afterward, a comprehensive urine and blood drug screen can be ordered as coingestions have now become a common occurrence. Comprehensive urine and blood drug screens are particularly important because they check for substances that do not appear on standard urine drug tests, such as synthetic opiates (e.g., fentanyl).²⁷ It is important to note that limitations for both standard and comprehensive urine drug screens do exist. Standard urine drug screens, performed by immunoassay, can yield false positives owing to their poor specificity. False-positive results on standard urine drug screens can be explained by their tendency to cross-react with other substances.²⁹ For example, commonly prescribed medications and over-the-counter drugs can yield false-positive results in these immunoassays. These medications include nonsteroidal anti-inflammatory drugs, proton pump inhibitors, promethazine, efavirenz, and hemp.³⁰ Therefore, a positive result on a standard urine drug screen should be followed by confirmatory testing with comprehensive urine and blood tests. In the case of Δ9-THC and cannabinoids, the positive predictive value can be as high as 100% when using these confirmatory tests, indicating that positive results on the initial urine drug screen are accurate true positives.³¹ Limitations to the confirmatory comprehensive urine and blood drug screens include the amount of time it takes for the test to be completed and for results to be obtained.

Adolescents who experience adverse effects like agitation or anxiety can be managed with benzodiazepines in acute and inpatient settings.²⁷ Severe side effects are becoming more common because of increasing potencies of Δ9-THC in cannabis products. As previously discussed, the potential for coingestion of cannabis with other substances should also be considered.

The current practice of addressing the ingestion of a substance, such as cannabis edibles, is to seek out emergency-level care and to contact a local poison control center at 1-800-222-1222. Consultation of subspecialists, particularly Child Protection Physicians who are specifically trained in areas of child abuse and neglect, is warranted should those concerns arise. Often, Child Protective Services and/or a Special Victims Unit collaborate with the primary medical team to aid in the safe disposition of the patient.

Risk Factors for Increased Adverse Effects After Acute Cannabis Ingestion

Younger children are at a higher risk of developing life-threatening symptoms with cannabis poisoning, including respiratory depression, seizures, and coma, potentially due to their higher number of CB1 receptors compared with adults.^16,17 Severe cases of respiratory depression, most commonly in children younger than age 5 who ingest Δ9-THC–containing products, may require assisted ventilation.^32,33 This effect is thought to be a result of interactions between Δ9-THC metabolites and CB1 receptors in brain regions that regulate breathing.³⁴

There has been very limited research in rodent models to assist in predicting the lethal dose of Δ9-THC in adults. These studies have several limitations, including known variations between male and female subjects and across different rat strains used.^35,36 It is also extremely difficult to account for differences in the absorption of intravenously administered Δ9-THC compared with orally ingested Δ9-THC. Recently, new molecular versions of THC have emerged (e.g., Δ8-THC and Δ10-THC), which have different properties and potencies than that of Δ9-THC. This, along with the current inconsistencies in the ratios of THC and CBD found in cannabis edibles, further complicates the ability to predict how much of an edible is excessive and may lead to complications.³⁷ Rather than trying to develop a cutoff for a lethal dose of Δ9-THC, there may be more utility in defining a threshold that is associated with an increased risk for more severe complications, especially for the pediatric population. In a recent study by Pepin et al,²⁴ it was found that a dose of Δ9-THC that is greater than or equal to 1.7 mg/kg is highly predictive of causing prolonged and severe toxicity in pediatric patients younger than age 6. If a Δ9-THC ingestion exceeds this 1.7 mg/kg threshold in a patient younger than age 6, inpatient hospital admission with prompt interventions is highly recommended. A table has been created from these findings by Pepin et al²⁴ to highlight the potential toxic doses of Δ9-THC based on actual body weight in kilograms and pounds for a pediatric patient younger than 6 years of age (Supplement Table S1). Pepin et al²⁴ proposed the use of this threshold to determine the timing of initial symptoms and to guide the management of pediatric patients due to the high level of probability of a severe (92.9%) and prolonged (87.3%) overdose. It is important to note that because 10 mg of Δ9-THC is a common serving size of cannabis edible products, children do not have to consume many candies or other cannabis edibles to surpass the threshold that could be toxic to them.²⁴ For example, an average 3- or 4-year old weighing approximately 16 kg (35.2 lbs) would only have to consume about 3 gummies at 10 mg each to achieve a dose that would exceed the 1.7 mg/kg threshold mentioned.^24,38 Unfortunately, cannabis edibles also come in serving sizes greater than 10 mg (e.g., 100-mg THC gummy bears), placing pediatric patients in harm’s way even quicker and to a greater degree when consumed. Table 2 has been included to illustrate the typical dosing ranges for certain cannabis edible products. Of note, there are limited reliable resources detailing these typical dosing ranges, and inconsistent regulatory oversight from a manufacturing standpoint makes it difficult to assess whether these assigned ranges are accurate. It is also important to be aware that there is significant variation and overlap among edible products and their typical dosing ranges. For example, cannabis gummies are frequently found with doses ranging from 1 to 100+ mg of Δ9-THC.^39,40 Recently, newer gummies have been introduced to the market with doses exceeding 1000 mg.⁴¹ This, along with the ability for consumers to make their own edibles at home, makes it extremely difficult to predict the dose of Δ9-THC ingested by a patient even if the type of edible product consumed is known.

Table 2.

Typical Doses Associated With Various Cannabis Edible Products

Edible Product Type	Amount of THC Per Dose, mg*
Low-dose/partial gummies, mints	1–2.5
Gummies, infused seltzers, honey sticks	3–5
Gummies, chocolates, single dose baked goods, candies, savory snacks, some beverages	10–15
Gummies, chocolate bars, other candies, infused condiments	20–30
Infused shots, sodas, tinctures, gummies, chocolates	50–100+

THC, tetrahydrocannabinol

Information adapted from Tyszko³⁹ and Sulak et al.⁴⁰

^*Amounts of THC present in different edibles may vary significantly. Check package labeling.

Recommendations and Future Considerations

No antidotes currently exist for Δ9-THC or CBD overdoses, unlike acetaminophen (acetylcysteine) or opioids (naloxone).^42–44 However, Anebulo Pharmaceuticals is conducting phase 2 trials for a potential antidote (ANEB-001) for acute cannabinoid toxicity as of December 2024.⁴⁵

Pediatricians and primary care providers often give anticipatory guidance to prevent accidental cannabis edible ingestion. Recommendations include using opaque, child-resistant packaging with universal Δ9-THC symbols and storing edibles in locked containers away from household snacks and out of children’s reach.^46,47

Currently, some institutions use clinical pathways to assess and treat children with known and/or presumed ingestions of toxic substances. One specific resource to note is the Children’s Hospital of Philadelphia’s “Inpatient Clinical Pathway for Children with Known or Presumed Toxic Ingestions.”⁴⁸ As the prevalence of acute cannabis intoxications continues to increase, there is potential for the collaboration of hospitals and poison control centers throughout the United States to continue to develop standardized clinical pathways that aim to support clinicians in the treatment of these complex situations. Additionally, there is an opportunity for these institutions to create a validated severity classification system to categorize a patient’s symptomatic presentation, aiding triage, management, and care. Furthermore, patient case simulations involving cannabis edible ingestions and intoxications should be integrated as an educational supplement to residency programs, particularly for those training in pediatrics or emergency medicine.

If a child presents to the emergency department with signs and symptoms that are suspicious and could be a result of cannabis use or accidental exposure, it is important that healthcare professionals conduct a thorough evaluation by asking the right questions and, by doing so, using the proper verbiage. There are many different ways in which cannabis can be formulated and administered. A thorough probing of the pediatric patient’s parents, guardians, or caregivers should be conducted. Possible questions may include the following:

1. Do you possess or have available any marijuana, cannabis, Δ8-THC, Δ9-THC, Δ10-THC, CBD, or any other cannabis-derived products?⁴⁹

2. In what form are these products available and/or how are they used?

   1. Smoking, vaping, ingesting through edibles/food, sublingual tinctures, infused drinks and/or teas, topicals/creams/ointments, or any other forms?⁵⁰

3. Where are these products stored? What does the packaging look like? Does the packaging emit any smell? Are your children aware of their availability in the home, or are they unaware? Have your children ever expressed an interest in them?⁴⁶

4. If they exist as edibles or food:

   1. Are these products available as: gummies, soft or hard candies, brownies, muffins, baked goods, infused drinks/teas, or other food items?⁵⁰
   2. What is the dose per serving? How many doses are in the container you have at home?
   3. Did you bring the labeling, packaging, or product with you?²⁴

Poison control centers keep records regarding acute cannabis edible ingestions, some of which have been used in prior studies to examine regional trends throughout the United States.¹¹ However, these data are not made readily available to clinicians frequently and are not systematically organized to inform broader clinical practice or policy. A separate registry or database accessible to all healthcare professionals could complement existing resources and provide meaningful, actionable insights. This database could systematically track and highlight recent patterns of accidental cannabis edible ingestions, including associations with particular product types (e.g., brownies, cookies, gummies, etc.), manufacturers, and packaging features such as shape, color, or labeling. By increasing awareness of these trends, the data could influence reforms to the current regulations and laws regarding product package design, ultimately aiming to prevent further unintentional ingestions. This database may also enable clinicians to report patient cases and treatment strategies, supporting revisions to current treatment protocols across various institutions.

Health system or government-sponsored quality improvement projects should promote lock boxes for marijuana edibles, similar to those for medications or weapons, especially in states where cannabis use is legal. Storage of these products “up and away” or “out of sight” may also reduce the curiosity or access that children may have to them.⁵⁰ These recommendations, combined with child-resistant packaging, would help to separate cannabis products from other household snacks and add an additional layer of safety to prevent child exposures.⁴⁶ Prospective research studies can further assess the effectiveness of this intervention for broader implementation.

At the national level, advocacy for further research on the content, potencies, and pharmacokinetic and pharmacodynamic properties of cannabis products is critical. Further emphasis on toxicological research in the pediatric population would be useful to enhance the understanding of how to treat these ingestion or intoxication cases. This may include differentiating between Δ9-THC–only versus CBD-only intoxications to assess for any differences in patient presentation, management, and subsequent outcomes. In addition, advocating for stricter regulation of the production, manufacturing, packaging, labeling, and distribution of cannabis edibles or other products by a governmental oversight entity (e.g., Food and Drug Administration) should be supported and encouraged. This entity should be granted the authority to establish standards for maximum product potencies and requirements for complete and accurate edible product labeling.

The public will benefit from more education regarding harm reduction and prevention strategies. Community outreach initiatives should educate people on the dangers and risks associated with the usage of all forms of cannabis products. General medication safety and education opportunities for children in the home should also be highlighted during these initiatives.⁵¹ Dispensary employees should be adequately trained and prepared to educate customers about the risks of storing cannabis products in the home, strategies to prevent accidental ingestion, and the appropriate actions to take should an accidental ingestion by a child or other unintended person occur. Further consideration of the potential need for pharmacists to be present in medical marijuana dispensaries should also take place. This includes discussing the associated responsibilities and/or legal liability for pharmacists that are likely to develop, as these dispensaries are not licensed pharmacies. This discussion is even more relevant now with the consideration of rescheduling marijuana to a lower-level scheduled substance within the Federal Controlled Substances Act. This rescheduling would potentially require marijuana to be dispensed by licensed pharmacists from licensed pharmacies.

Conclusion

As marijuana legalization increases, the prevalence of cannabis edibles presents a significant risk to children. Children cannot differentiate between cannabis edibles and regular snacks and are more vulnerable to lower toxic doses of Δ9-THC. The clinical management of cannabis intoxication is challenging because of the wide variety and potency of these products. Future research should focus on the contents and potencies of cannabis edibles, as well as their pharmacokinetic and toxicokinetic profiles in pediatric patients. Clinical treatment pathways and protocols are needed in hospitals, urgent care centers, and emergency departments to guide clinicians in managing these complex situations. Validated screening tools should be developed to support clinicians during the initial assessment and interval history of patients with suspected cannabis edible ingestions. Immediate advocacy is needed to strengthen oversight of the regulation, production, packaging, and labeling of cannabis products. Community education and prevention programs should be supported to reduce the risk of accidental cannabis ingestions, especially among children, the most vulnerable among us. These efforts aim to prevent harm and negative outcomes for our pediatric patients.

ABBREVIATIONS

Δ9-THC

delta-9-tetrahydrocannabinol

CBD

cannabidiol

THC

tetrahydrocannabinol